BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, November 7, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» Myrobalan to use series A funding for CNS neurorestorative therapies
To read the full story,
subscribe
or
sign in
.
Neurology/Psychiatric
Myrobalan to use series A funding for CNS neurorestorative therapies
Jan. 11, 2024
Myrobalan Therapeutics Inc. has completed a $24 million series A funding to support development of neurorestorative therapies for CNS diseases.
BioWorld Science
Financings
Neurology/psychiatric
Series A
